Ask AI
Optimizing Shingles Vaccine Uptake

CE / CME

Optimizing Shingles Vaccination: Current Trends and Expert Strategies for Improving Uptake and Series Completion

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Released: January 30, 2026

Expiration: January 29, 2027

Activity

Progress
1 2 3
Course Completed

References

  1. Centers for Disease Control and Prevention. Shingles facts and stats. cdc.gov/shingles/data-research/index.html. Accessed January 21, 2026.
  2. Centers for Disease Control and Prevention. Clinical overview of shingles (herpes zoster). cdc.gov/shingles/hcp/clinical-overview.html. Accessed January 21, 2024.
  3. Koshy E, Mengting L, Kumar H, et al. Epidemiology, treatment and prevention of herpes zoster: A comprehensive review. Indian J Dermatol Venereol Leprol. 2018;84:251-262.
  4. Dommasch ED, Joyce CJ, Mostaghimi A. Trends in nationwide herpes zoster emergency department utilization from 2006 to 2013. JAMA Dermatol. 2017;153:874-881.
  5. Anderson TC, Masters NB, Guo A, et al. Use of recombinant zoster vaccine in immunocompromised adults aged ≥19 years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:80-84.
  6. Center for Disease Control and Prevention. Shingles vaccination. cdc.gov/vaccines/vpd/shingles/index.html. Accessed January 21, 2026.
  7. Zoster vaccine recombinant [prescribing information]. Durham, NG: GlaxoSmithKline; 2025.
  8. Centers for Disease Control and Prevention. Clinical considerations for Shingrix use in immunocompromised adults aged ≥19 years. cdc.gov/shingles/hcp/vaccine-considerations/immunocompromised-adults.html. Accessed January 21, 2026.
  9. Centers for Disease Control and Prevention. Vaccination coverage among adults in the United States, National Health Interview Survey, 2021. cdc.gov/adultvaxview/publications-resources/vaccination-coverage-adults-2021.html. Accessed January 21, 2026.
  10. LaMori J, Feng X, Pericone CD, et al. Real-world evidence on adherence and completion of the two-dose recombinant zoster vaccine and associated factors in U.S. adults, 2017-2021. Vaccine. 2022;40:2266-2273.
  11. Scalia P, Durand MA, Elwyn G. Shared decision-making interventions: An overview and a meta-analysis of their impact on vaccine uptake. J Intern Med. 2022;291:408-425. 
  12. Centers for Disease Control and Prevention. ACIP shared clinical decision-making recommendations. cdc.gov/acip/vaccine-recommendations/shared-clinical-decision-making.html. Accessed January 21, 2026.
  13. National Vaccine Advisory Committee. Recommendations from the National Vaccine Advisory committee: standards for adult immunization practice. Public Health Rep. 2014;129:115-23. 
  14. Centers for Disease Control and Prevention. Foster support for vaccination in your practice. cdc.gov/vaccines/hcp/conversations/your-practice.html. Accessed January 21, 2026.
  15. Centers for Disease Control and Prevention. Recombinant zoster vaccine VIS. cdc.gov/vaccines/hcp/current-vis/shingles.html. Accessed January 21, 2026.
  16. The Community Guide. Vaccine programs: health care system-based interventions implemented in combination. thecommunityguide.org/findings/vaccination-programs-health-care-system-based-interventions-implemented-combination.html. Accessed January 21, 2026.
  17. Gershman J. Pharmacists are vital to transitions of care. pharmacytimes.com/view/pharmacists-are-vital-to-transitions-of-care. January 21, 2026.
  18. American Society of Health-System Pharmacists. The ambulatory care career tool. ashp.org/-/media/assets/pharmacy-practice/resource-centers/ambulatory-care/ambulatory-care-career-tool.ashx. Accessed January 21, 2026.
  19. Zerbo O, Bartlett J, Fireman B, et al. Effectiveness of recombinant zoster vaccine against herpes zoster in a real-world setting. Ann Intern Med. 2024;177:189-195.
  20.  Williams LR, Hombach J, Marti M. Evaluating the immunogenicity, efficacy, and effectiveness of recombinant zoster vaccine for global public health policy. Vaccines (Basel). 2025;13:250.
  21. Centers for Disease Control and Prevention. Shingles vaccination. cdc.gov/shingles/vaccines/index.html. Accessed January 21, 2026.
  22. Dooling KL, Guo A, Patel M, et al. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018;67:103-108.
  23. Dehghani A, Yendewa G. Zoster vaccination in people living with HIV is associated with reduced mortality and cardiovascular risk: a real-world matched cohort study zoster infection & vaccination as determinants of vascular and cognitive outcomes in PLWH/ Presented at IDWeek 2025; October 19-22, 2025. Abstract 218.
  24. Stempniewicz N, Steffens A, Zhu Y, et al. Incidence of diagnosed herpes zoster and risk of complications by race and ethnicity: a retrospective cohort study among adults in the United States. Presented at IDWeek 2024; October 16-19, 2024. Abstract P-2343.
  25. Singer D, Stempniewicz N, Lee L, et al. Disparities in recombinant zoster vaccine coverage in the United States. Popul Health Manag. 2025;28:288-297.
  26. Graves C, Wright WL, Wolynn TH. Using behavioral science to help understand vaccine hesitancy. EMJ Microbiol Infect Dis. 2023;4(Suppl 1):2-7.
  27. Gagneur A. Motivational interviewing: a powerful tool to address vaccine hesitancy. Can Commun Dis Rep. 2020;46:93-97.
  28. Parrish-Sprowl J, Thomson A, Johnson RD, et al. The AIMS approach: regulating receptivity in patient-provider vaccine conversations. Front Public Health. 2023;11:1120326.
  29. Agency for Healthcare Research and Quality. The SHARE approach. ahrq.gov/sdm/share-approach/index.html. Accessed January 21, 2026.
  30. National Vaccine Advisory Committee. Recommendations from the National Vaccine Advisory committee: standards for adult immunization practice. Public Health Rep. 2014;129:115-23.
  31. Abdul-Mutakabbir JC, Casey S, Jews V, et al. A three-tiered approach to address barriers to COVID-19 vaccine delivery in the Black community. Lancet Glob Health. 2021;9:e749-e750.